Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA5A | P35218 | 1/20 | 0.68 |
| ▸ | CA7 | P43166 | 1/20 | 0.68 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 4/20 | 0.64 |
| ▸ | MAOA | P21397 | 5/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28440656 | 0.85 | MAOB (0.71) | MAOBCA12CA1CA2CA4 | |
| SCHEMBL29724495 | 0.85 | MAOB (0.71) | MAOBCA12CA1CA2CA4 | |
| SCHEMBL28373047 | 0.84 | SLC16A3 (0.75) | MAOBCA12CA1CA2CA4 | |
| SCHEMBL5617763 | 0.84 | NPC1 (0.74) | MAOBCA12CA1CA2CA4 | |
| SCHEMBL5618032 | 0.81 | MAOB (0.77) | MAOBACHEMAOAAR | |
| SCHEMBL5618481 | 0.79 | MAOB (0.77) | MAOBCA12CA1CA2CA4 | |
| SCHEMBL7309342 | 0.79 | CA12 (0.52) | MAOBCA12CA1CA2CA4 | |
| SCHEMBL10140560 | 0.78 | HSD17B3 (0.60) | MAOBCA12CA1CA2CA4 | |
| SCHEMBL5617810 | 0.78 | NPC1 (0.76) | MAOBCA12CA1CA2CA4 | |
| SCHEMBL7438868 | 0.78 | TDP1 (0.75) | MAOBARRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-0363793-B1 | ARYL ALKOXY COUMARINS, PROCESS FOR THEIR PRODUCTION AND THERAPEUTIC AGENTS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1993-04-21 | — | — | EP | disclosed |
| US-5100914-A | Monoamine Oxidase Inhibitors, Central Nervous System Disorders | BASF AKTIENGESELLSCHAFT (DE) | 1992-03-31 | — | — | US | disclosed |
| EP-0363793-A1 | Aryl alkoxy coumarins, process for their production and therapeutic agents containing them | BASF Aktiengesellschaft (DE) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885CA12 4798/4885CA1 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.